Aclaris Therapeutics ACRS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2M+54.1% | $1.3M-60.7% | $3.3M+85.6% | $1.78M+22.1% | $1.46M-84.2% | ||
| $395K-25.8% | $532K-1.1% | $538K+4.5% | $515K+1.8% | $506K-28.2% | ||
| $15.66M-5.6% | $16.58M+27.3% | $13.03M+13.8% | $11.45M-1.2% | $11.58M+28.3% | ||
| $6.74M+20.9% | $5.58M+14.5% | $4.87M-9.6% | $5.39M-12.3% | $6.14M+23.9% | ||
| $102K0.0% | $102K-7.3% | $110K-3.5% | $114K-10.9% | $128K-10.5% | ||
| $24.19M+0.7% | $24.03M+17.5% | $20.45M+1.3% | $20.19M+3.3% | $19.54M-82.1% | ||
| -$22.19M+2.4% | -$22.73M-32.6% | -$17.15M+6.8% | -$18.41M-1.8% | -$18.08M+81.9% | ||
| -1,111.8%+644pp | -1,755.5%-1,236pp | -519.8%+516pp | -1,035.9%+207pp | -1,242.9%-161pp | ||
| $1.51M-7.3% | $1.63M-10.2% | $1.82M-9.9% | $2.02M-6.8% | $2.17M+3.0% | ||
| $2.37M-19.4% | $2.94M+15.9% | $2.54M-14.9% | $2.98M-0.7% | $3M-4.0% | ||
| -$19.82M-0.1% | -$19.8M-35.5% | -$14.61M+5.3% | -$15.43M-2.3% | -$15.09M+84.4% | ||
| -993.2%+535pp | -1,528.6%-1,086pp | -443%+425pp | -868.3%+169pp | -1,036.8%+11.5pp | ||
| -$0.15+6.3% | -$0.16-33.3% | -$0.12+7.7% | -$0.13-8.3% | -$0.12+90.1% | ||
| -$0.15+6.3% | -$0.16-33.3% | -$0.12+7.7% | -$0.13-8.3% | -$0.12+90.1% | ||
| 128.8M+5.1% | 122.6M0.0% | 122.6M0.0% | 122.6M+0.2% | 122.4M+58.3% | ||
| 128.8M+5.1% | 122.6M0.0% | 122.6M0.0% | 122.6M+0.2% | 122.4M+58.3% | ||
| —— | $400K+300% | $100K-93.3% | $1.5M+400% | $300K— | ||
| -$20.41M-3.2% | -$19.78M-36.4% | -$14.5M+5.7% | -$15.38M-4.3% | -$14.75M+84.8% | ||
| —— | —— | —— | —— | —— | ||
| $1.39M+48.7% | $937K-51.0% | $1.91M+43.1% | $1.34M+32.2% | $1.01M-88.3% | ||
| -$588K-4,623% | $13K-88.7% | $115K+140% | $48K-85.8% | $337K— | ||
| -$588K-4,623% | $13K-88.7% | $115K+140% | $48K-85.8% | $337K— | ||
| $2M+54.1% | $1.3M-60.7% | $3.3M+85.6% | $1.78M+22.1% | $1.46M-84.2% | ||
| $854K-34.6% | $1.31M+82.3% | $716K-25.5% | $961K+15.4% | $833K-18.3% | ||
| -$22.19M+2.4% | -$22.73M-32.6% | -$17.15M+6.8% | -$18.41M-1.8% | -$18.08M+81.9% | ||
| -$22.09M+2.4% | -$22.63M-32.8% | -$17.04M+6.9% | -$18.29M-1.9% | -$17.96M+82.0% | ||
| -$22.09M+2.4% | -$22.63M-32.8% | -$17.04M+6.9% | -$18.29M-1.9% | -$17.96M+82.0% | ||
| -1,106.7%+641pp | -1,747.6%-1,231pp | -516.5%+513pp | -1,029.5%+205pp | -1,234.1%-154pp | ||
| -$22.19M+2.4% | -$22.73M-32.6% | -$17.15M+6.8% | -$18.41M-1.8% | -$18.08M+81.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics (ACRS) generated $8.4M in revenue over the trailing twelve months, down 52.9% year over year.
- Is Aclaris Therapeutics profitable?
- Aclaris Therapeutics is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -832.6% net margin.
- What are Aclaris Therapeutics's profit margins?
- Gross margin is 76.3% and operating margin is -961.9%, with a -832.6% net margin.
- What is Aclaris Therapeutics's earnings per share?
- Aclaris Therapeutics's diluted EPS over the trailing twelve months is $-0.56.
- Where does Aclaris Therapeutics's income statement data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
